source
- Beacon eye gene therapy hits mark in late-stage studyBeacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.
- Xenon shares tumble up to 30% after pausing depression trial over neuropsychiatric eventsXenon Pharmaceuticals announced it is pausing enrollment in its depression trial for the drug azetukalner after neuropsychiatric adverse events emerged that were not observed in earlier testing. A…